Showing results (211-220 of 276) with videos related to

Sort By:
Pageof 28
Annals of Surgical Oncology|November 30, 2016
Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer: A Subgroup Analysis of the AGO-CaRE-1 StudyRüdiger Klapdor, Peter Hillemanns, Linn Wölber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 3, 2025
Atezolizumab With Bevacizumab and Nonplatinum Chemotherapy for Recurrent Ovarian Cancer: Final Results From the Placebo-Controlled AGO-OVAR 2.29/ENGOT-ov34 Phase III TrialPhilipp Harter, Frederik Marmé, Andrés Redondo, et al.
The New England Journal of Medicine|December 19, 2019
Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian CancerIsabelle Ray-Coquard, Patricia Pautier, Sandro Pignata, et al.
Geburtshilfe Und Frauenheilkunde|October 29, 2019
Sarcoma of the Uterus. Guideline of the DGGG and OEGGG (S2k Level, AWMF Register Number 015/074, February 2019)Dominik Denschlag, Sven Ackermann, Marco Johannes Battista, et al.
The New England Journal of Medicine|December 7, 2021
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian CancerPhilipp Harter, Jalid Sehouli, Ignace Vergote, et al.
Cancers|March 10, 2022
Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 TrialJean-David Fumet, Emilie Lardenois, Isabelle Ray-Coquard, et al.
Geburtshilfe Und Frauenheilkunde|December 5, 2022
Sarcoma of the Uterus. Guideline of the DGGG, OEGGG and SGGG (S2k-Level, AWMF Registry No. 015/074, April 2021)Dominik Denschlag, Sven Ackermann, Marco Johannes Battista, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2013
Abagovomab as maintenance therapy in patients with epithelial ovarian cancer: a phase III trial of the AGO OVAR, COGI, GINECO, and GEICO--the MIMOSA studyPaul Sabbatini, Philipp Harter, Giovanni Scambia, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 1, 2021
Ovarian Cancer-Specific <i>BRCA</i>-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 TrialPhilip C Schouten, Lisa Richters, Daniel J Vis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2022
Optimal Treatment Duration of Bevacizumab as Front-Line Therapy for Advanced Ovarian Cancer: AGO-OVAR 17 BOOST/GINECO OV118/ENGOT Ov-15 Open-Label Randomized Phase III TrialJacobus Pfisterer, Florence Joly, Gunnar Kristensen, et al.
Pageof 28